AstraZeneca expands 1st-line lung cancer Immuno-Oncology programme opportunities

Click here to view online. Add this email to your safelist.

17 January 2017

AstraZeneca today provides an update on its Immuno-Oncology (IO) late-stage clinical development programme in 1st-line non-small cell lung cancer (NSCLC), including a refinement of the Phase III MYSTIC trial.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.